Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 5
1992 2
1993 10
1994 1
1995 5
1996 2
1997 2
1998 5
1999 3
2000 5
2001 3
2002 6
2003 3
2004 5
2005 3
2006 4
2007 2
2008 3
2009 5
2010 4
2011 5
2012 5
2013 1
2014 3
2015 2
2016 1
2017 6
2018 2
2021 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 7570000

103 results

Results by year

Filters applied: . Clear all
Page 1
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. Blaese RM, et al. Science. 1995 Oct 20;270(5235):475-80. doi: 10.1126/science.270.5235.475. Science. 1995. PMID: 7570001 Clinical Trial.
Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM, Culver KW, Chang L, Anderson WF, Mullen C, Nienhuis A, Carter C, Dunbar C, Leitman S, Berger M, et al. Blaese RM, et al. Hum Gene Ther. 1993 Aug;4(4):521-7. doi: 10.1089/hum.1993.4.4-521. Hum Gene Ther. 1993. PMID: 7691188
Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M, Yamada M, Nakajima S, Kida M, Maeyama Y, Hatano N, Toita N, Takezaki S, Okura Y, Kobayashi R, Matsumoto Y, Tatsuzawa O, Tsuchida F, Kato S, Kitagawa M, Mineno J, Hershfield MS, Bali P, Candotti F, Onodera M, Kawamura N, Sakiyama Y, Ariga T. Otsu M, et al. J Clin Immunol. 2015 May;35(4):384-98. doi: 10.1007/s10875-015-0157-1. Epub 2015 Apr 15. J Clin Immunol. 2015. PMID: 25875699
103 results